1、Characterization of unresectable cholangiocarcinoma patients treated with or without chemoradiationAuthor(s): Jane Elizabeth RogersDepartment of Pharmacy Clinical Programs, The University of Texas MD Anderson Cancer Center, Houston, TXJ Clin Oncol 33, 2015 (suppl 3; abstr 403)Reporter DR pengyingBac
2、kground Curative treatment for CC is surgical resection. Unfortunately, most CC patients (pts) present with unresectable disease in which gemcitabine plus platinum (GEM-P) chemotherapy is the mainstay of treatment (tx). Advanced CC has a dismal prognosis with 5-year survival reported at 5-10 %. Data
3、 regarding chemoradiation (CRT) in pts with unresectable CC (uCC) remains limited. Introduction Biliary tract cancers,including cholangiocarcinoma (CC) and gallbladder cancers, are rare with limited data ragarding treatment. Most patients present with unresectable CC resulting in a poor prognosis. C
4、RT is the mainstay of treatment for uCC. There is limited data regarding localized therapy with CRT.Methods We retrospectively reviewed uCC pts from 1/1/2009 to 7/31/2013. Primary objective: Determine the percentage of pts treated with CRTEvaluate the median number of chemotherapy cycles given prior
5、 to CRT Secondary objectives: Disease response to first-line txDuration of CRT controlProgression-free survival (PFS) with or without CRToverall survival (OS) with or without CRT Inclusion criteria: uCC diagnosis, received tx, and had follow-up at our institution. Exclusion criteria: pts who receive
6、d liver-directed therapy other than CRT, mixed histology tumors, and a history of other malignancies.Results 114 pts were included with 62% having intrahepatic CC. Median age: 63 Gender: females (53.5%); male (46.5%). Site of disease: intra (62%), Hilar (24%), Extra (14%) . 65% of pts received CRT(7
7、% radiation alone) with a median of 6(range 0-26) chemotherapy cycles given prior to CRT. 66% received gemcitabine + platinum (cisplatin/oxaliplain) as ffirst-line treatment. Disease control (DC) (response + stable disease) with first-line tx was 75% with 71% receiving GEM-P +/- erlotinib first-line. DC after CRT was 62% with a median duration of radiation control of 6.4 mths. Median PFS and OS for all pts were 13.4 mths and 27.8 mths, respectively.
